Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have chosen to take part voluntarily and have signed a consent form
• Adults aged 18 to 75 years old, of any gender
• People diagnosed with advanced pancreatic cancer (either spread to other parts of the body or unable to be removed by surgery), with at least one measurable area of disease visible on scans
• People with a good general level of physical functioning — able to carry out normal daily activities with little or no limitation (rated 0 or 1 on a standard performance scale)
• People whose life expectancy is estimated to be at least 12 weeks
• People with adequate bone marrow and organ function based on blood tests (confirm with trial site for specific values)
• Women of childbearing age who have had a negative pregnancy test within one week before starting the study treatment, and who are willing to use an effective form of contraception during the study and for three months after the last dose
• Men whose partners could become pregnant, who agree to use effective contraception during the study and for six months after the last dose

Who may not be able to join:

• People with a known allergy to the study drug or any of its ingredients
• People who received cancer treatment in the four weeks before starting the study, or who completed palliative radiotherapy within 14 days before the first dose
• People who have had another active cancer in the past five years
• People who have cancer that has spread to the brain or spinal cord that has not been treated or is currently active
• People who have not yet recovered from side effects of previous treatments to an acceptable level (confirm with trial site for specific details)
• People with interstitial lung disease, non-infectious lung inflammation, severe uncontrolled medical conditions, active infections, or who have had a major operation within the past 28 days or have not yet recovered from one
• People who have had a bowel blockage, or signs of one, in the six months before starting treatment — unless surgery has fully resolved the blockage
• People who have had a serious blood clot in the heart, brain, or blood vessels in the six months before joining the study
• People with immune system conditions present from birth or acquired (such as HIV infection), or those with active hepatitis B or hepatitis C at levels above specified thresholds (confirm with trial site for exact values)
• People with active tuberculosis in the past year, or a history of tuberculosis from more than a year ago that was never properly treated
• People who are currently in another clinical trial, or whose last dose in a previous clinical trial was less than four weeks ago (or within five half-lives of that study drug, whichever is shorter)
• People considered to be at high risk of pancreatitis, including those with elevated levels of certain enzymes (amylase and/or lipase) at three times or more above the normal upper limit
• People with uncontrolled mental health conditions, or other factors that may affect their ability to complete the study — such as alcohol, drug, or substance misuse, or legal detention
• People who have had a major surgery (other than for diagnosis or biopsy) within 28 days before the first dose, or a minor invasive procedure (such as a biopsy, endoscopy, or drainage procedure) within seven days before the first dose
• People whom the trial investigators consider unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.